Drug – bio-affecting and body treating compositions – Topical body preparation containing solid synthetic organic... – Ophthalmic preparation
Reexamination Certificate
2008-04-01
2008-04-01
Davis, Ruth A (Department: 1651)
Drug, bio-affecting and body treating compositions
Topical body preparation containing solid synthetic organic...
Ophthalmic preparation
C424S400000, C424S427000
Reexamination Certificate
active
10510585
ABSTRACT:
The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one non-nucleotide or non-protein agent that inhibits expression and/or signaling of connective tissue growth factor (CTGF).
REFERENCES:
patent: 5408040 (1995-04-01), Grotendorst et al.
patent: 5585270 (1996-12-01), Grotendorst et al.
patent: 5594015 (1997-01-01), Kurtz et al.
patent: 6069006 (2000-05-01), Grotendorst et al.
patent: 6150101 (2000-11-01), Grotendorst et al.
patent: 6190884 (2001-02-01), Grotendorst et al.
patent: 6232064 (2001-05-01), Grotendorst et al.
patent: 6316465 (2001-11-01), Pershadsingh et al.
patent: 6348329 (2002-02-01), Schmidt et al.
patent: 6358741 (2002-03-01), Schmidt et al.
patent: 2004/0005319 (2004-01-01), Grotendorst et al.
patent: 2002 36641 (2003-06-01), None
patent: WO 00/30628 (2000-06-01), None
patent: WO 01/25226 (2001-04-01), None
patent: WO 01/60374 (2001-08-01), None
patent: WO 01/70727 (2001-09-01), None
patent: WO 02/13812 (2002-02-01), None
patent: WO 03/027275 (2003-04-01), None
patent: WO 03/049773 (2003-06-01), None
patent: WO 03/049773 (2003-06-01), None
patent: WO 03/092584 (2003-11-01), None
Bain, J., H. McLauchlan, et al., “The Specificities of protein kinase inhibitors: an update” BIOCHEM J 371(Pt 1): 199-204 (2003).
Coghlan, M. P. et al., “Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription” CHEM BIOL 7(10):793-803 (2000).
Cohen, P. and Frame, S., “The renaissance of GSK3” Nat Rev Mol Cell Biol 2(10):769-776 (2001).
Davis, S. T. et al., “Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors” SCIENCE 291(5501):134-137 (2001).
Hardcastle, I. R. et al., “Designing inihibitors of cyclin-dependent kinases” Annu Rev Pharmacol Toxicol 42:325-348 (2002).
Knockaert, M. et al., “Pharmacological inhibitors of cyclin-dependent kinases” Trends Pharmacol Sci 23(9):417-425 (2002).
Kothapalli, D. and Grotendorst, G.R., “CTGF modulates cell cycle progression in cAMP-arrested NRK fibroblasts” J Cell Physiol 182(1):119-126 (2000).
Leost, M. et al., “Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25” Eur J Biochem 267(19):5983-5994 (2000).
Leske MC, et al., American Journal of Epidemiology, 118(2):166-191 (Aug. 1983).
Park, S. K., Kim, J., Seomun, Y., Choi, J., Kim, D. H., Han, I. O., Lee, E. H., Chung, S. K., Joo, C. K., “Hydrogen Peroxide is a Novel Inducer of Connective Tissue Growth Factor,” Biochem. Biophys. Res. Commun. 284(4):966-971 (2001).
Schwab, J. M., Postler, E., Nguyen, T. D., Mittelbronn, M., Meyermann, R., Schluesener, H. J., “Connective Tissue Growth Factor is Expressed by a Subset of Reactive Astrocytes in Human Cerebral Infarction,” Neuropathology and Appied. Neurobiology 26(5):434-440 (2000).
Schwab, J. M., Beschorner, R., Nguyen, T. D., Meyermann, R., Schluesener, H. J., Differential Cellular Accumulation of Connective Tissue Growth Factor Defines a Subset of Reactive Astrocytes, Invading Fibroblasts, and Endothelial Cells Following Central Nervous System Injury in.
Shepard et al., “Delayed Secondary Glucocorticoid Responsiveness of MYOC in Human Trabecular Meshwork Cells”, IOVS 42:3173-3181 (2001).
Strong, N. P., “How optometrists screen for glaucoma: A survey”, Ophthal. Physiol. Opt., 12:3-7 (1992).
Vaughan, D. et al., In: General Ophthalmology, Appleton & Lange, Norwalk, Conn., pp. 213-230 (1992).
Wang et al., “Optimal procedure for extracting RNA from human ocular tissues and expression profiling of the congential glaucoma gene FOXC1 using quantitativ RT-PCR”, Mol. Vis. 7:89-94 (2001).
Willson, T. M. et al., “The PPARs: from orphan receptors to drug discovery” J Med Chem 43(4):527-550 (2000).
Woodgett, J. R., “Judging a protein by more than its name: GSK-3” Science's STKE 2001(100):1-11 (2001).
Zaharevitz, D. W. et al., “Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases” Cancer Res 59(11):2566-2569 (1999).
Francesca et al., “Human Anti-Transforming Growth Factor-•2 Antibody: A New Glaucoma Anti-Scarring Agent”, IOVS, vol. 40:2225-2234, 1999.
Lefevre et al., “Involvement of Cyclin-Dependent Kinases in Axotomy Induced Retinal Ganglion Cell Death”, The Journal of Comparative Neurology, vol. 447:72-81, 2002.
Mass et al., “Apoptosis of Central and Peripheral Neurons Can Be Prevented with Cyclin-Dependent Kinase/Mitogen-Activated Protein Kinase Inhibitors”, Journal of NeuroChemistry, vol. 70:1401-1410, 1998.
Partial European Search Report dated Dec. 21, 2005 for corresponding EP Patent Application No. 05109789.7.
Clark Abbot F.
Fleenor Debra L.
Jacobson Nasreen
Pang Iok-Hou
Shepard Allan
Alcon Inc.
Davis Ruth A
Flanigan Mark E.
LandOfFree
Agents which regulate, inhibit, or modulate the activity... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Agents which regulate, inhibit, or modulate the activity..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Agents which regulate, inhibit, or modulate the activity... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3909141